Latest news with #Cytiva
Business Wire
18-06-2025
- Business
- Business Wire
Cytiva and Argonaut Collaborate to Expand Reagent Lyophilization Manufacturing in EU and US
AMERSHAM, United Kingdom & CARLSBAD, Calif.--(BUSINESS WIRE)--Cytiva and Argonaut Manufacturing Services Inc., 'Argonaut,' have established a contract manufacturing agreement to enhance reagent stabilization services and lyophilization capabilities for diagnostic assay developers globally. Lyophilization and reagent stabilization provides substantial benefits to both diagnostic companies and their customers including cost reduction, elimination of cold-chain logistics, and extended shelf-life. Additionally, these approaches are favourable for environmental stewardship (e.g. ESG initiatives) as they reduce emissions and carbon footprint. Lyophilization may also assist organizations in addressing the new ISO 9001 guidance on climate change. The collaboration will help diagnostic assay developers to access critical support services from the combined capabilities of both companies, gain the advantages of lyophilization capabilities at scale and access manufacturing facilities in both Europe and the US benefitting from: Reduced shipping costs and overall cost of goods reduction Shorter project timelines speeding up commercialization of tests Reduced emissions and carbon footprint promoting sustainable business practices 'Working together with Cytiva notably improves our manufacturing capacity, improving the service offered to our customers especially in the UK/EU marketplace. Putting our customer needs first is at the center of everything we do,' commented Stacy Sutton, General Manager of Life Sciences at Argonaut Manufacturing Services, Inc. Gabriel Fernandez de Pierola, General Manager of Diagnostic and Genomic Solutions at Cytiva, comments 'Feedback from our customers shows a preference towards local manufacturing for lyophilization projects and working with Argonaut to provide cGMP level manufacturing further helps to address evolving customer needs in the lyophilization space.' The partnership is anticipated to positively impact diagnostic assay development teams with immediate effect. About Cytiva At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15,000 associates in more than 40 countries, we're driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at About Argonaut Argonaut Manufacturing Services, Inc. is an FDA-registered cGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill/finish features state-of-the-art automated equipment for high yield filling of sterile injectable drugs including biologics, peptides, small molecule, and vaccines. Diagnostic manufacturing includes proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. Learn more at
Yahoo
18-06-2025
- Business
- Yahoo
Cytiva and Argonaut Collaborate to Expand Reagent Lyophilization Manufacturing in EU and US
Global Diagnostic Companies to Benefit with Faster Development & Manufacturing AMERSHAM, United Kingdom & CARLSBAD, Calif., June 18, 2025--(BUSINESS WIRE)--Cytiva and Argonaut Manufacturing Services Inc., "Argonaut," have established a contract manufacturing agreement to enhance reagent stabilization services and lyophilization capabilities for diagnostic assay developers globally. Lyophilization and reagent stabilization provides substantial benefits to both diagnostic companies and their customers including cost reduction, elimination of cold-chain logistics, and extended shelf-life. Additionally, these approaches are favourable for environmental stewardship (e.g. ESG initiatives) as they reduce emissions and carbon footprint. Lyophilization may also assist organizations in addressing the new ISO 9001 guidance on climate change. The collaboration will help diagnostic assay developers to access critical support services from the combined capabilities of both companies, gain the advantages of lyophilization capabilities at scale and access manufacturing facilities in both Europe and the US benefitting from: Reduced shipping costs and overall cost of goods reduction Shorter project timelines speeding up commercialization of tests Reduced emissions and carbon footprint promoting sustainable business practices "Working together with Cytiva notably improves our manufacturing capacity, improving the service offered to our customers especially in the UK/EU marketplace. Putting our customer needs first is at the center of everything we do," commented Stacy Sutton, General Manager of Life Sciences at Argonaut Manufacturing Services, Inc. Gabriel Fernandez de Pierola, General Manager of Diagnostic and Genomic Solutions at Cytiva, comments "Feedback from our customers shows a preference towards local manufacturing for lyophilization projects and working with Argonaut to provide cGMP level manufacturing further helps to address evolving customer needs in the lyophilization space." The partnership is anticipated to positively impact diagnostic assay development teams with immediate effect. About Cytiva At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15,000 associates in more than 40 countries, we're driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at About Argonaut Argonaut Manufacturing Services, Inc. is an FDA-registered cGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill/finish features state-of-the-art automated equipment for high yield filling of sterile injectable drugs including biologics, peptides, small molecule, and vaccines. Diagnostic manufacturing includes proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. Learn more at View source version on Contacts Argonaut Media Contact Name: Billy BurrisEmail: billy@ Phone: 609-458-8662
Business Wire
28-05-2025
- Business
- Business Wire
Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
CAMBRIDGE, England & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a collaboration with Cytiva, a global life sciences leader. This collaboration is focused on accelerating the production, purification and characterization of proteins required for drug research and development, enabled through the combination of Nuclera's eProtein Discovery System with Cytiva's Biacore™ surface plasmon resonance (SPR) technology. Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days. This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera's eProtein Discovery System was used to produce Bruton's Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized using Cytiva's Biacore SPR system. Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, commented: 'Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery's ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery's capability to streamline protein production workflows with Cytiva's Biacore protein characterization systems open a whole new avenue for accelerating drug development.' Anna Moberg, Senior Manager and Project Manager, Cytiva, added: 'The ability of Nuclera's eProtein Discovery to accelerate protein production and purification complements Cytiva's Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.' For more information about Nuclera's eProtein Discovery System, please visit:
Yahoo
28-05-2025
- Business
- Yahoo
Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
Collaboration combines Nuclera's eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva's Biacore SPR system, which characterizes molecular interactions Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions Showcased at Discovery on Target and PEGS Europe conferences, detailing the production and characterization of Bruton's Tyrosine Kinase, which is implicated in B-cell malignancies CAMBRIDGE, England & MARLBOROUGH, Mass., May 28, 2025--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a collaboration with Cytiva, a global life sciences leader. This collaboration is focused on accelerating the production, purification and characterization of proteins required for drug research and development, enabled through the combination of Nuclera's eProtein Discovery System with Cytiva's Biacore™ surface plasmon resonance (SPR) technology. Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days. This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera's eProtein Discovery System was used to produce Bruton's Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized using Cytiva's Biacore SPR system. Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, commented: "Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery's ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery's capability to streamline protein production workflows with Cytiva's Biacore protein characterization systems open a whole new avenue for accelerating drug development." Anna Moberg, Senior Manager and Project Manager, Cytiva, added: "The ability of Nuclera's eProtein Discovery to accelerate protein production and purification complements Cytiva's Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development." For more information about Nuclera's eProtein Discovery System, please visit: View source version on Contacts Media contact: Dr. Ben RutterZyme CommunicationsTel: +44(0)7920 770 935Email: Sign in to access your portfolio
Associated Press
27-05-2025
- Business
- Associated Press
Bora Biologics Expands San Diego Facility for 2000L+ Scale Biologics Manufacturing, Boosts CDMO Capacity
SAN DIEGO, CA / ACCESS Newswire / May 27, 2025 / Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego. This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics' position as a premier biologics CDMO. The expansion adds 8,075 square feet of state-of-the-art GMP manufacturing space to the San Diego biologics manufacturing facility, comprising a cutting-edge upstream mammalian cell culture hall, harvest suite with two inoculation rooms and in-process testing room, capture suite, and a downstream processing suite. This includes 6,950 square feet of new construction and 1,125 square feet of revisions to the existing GMP space. The expanded facility will feature two 2000L Cytiva XDR bioreactors and seed train, providing Bora Biologics' clients with robust and scalable biologics manufacturing solutions. The upstream hall's design allows for future bioreactor expansion up to 5000L scale. The downstream process suite is engineered to efficiently process up to 5000L modern high-titer cell culture processes, ensuring streamlined purification. Bora Biologics' San Diego facility currently offers a comprehensive range of GMP manufacturing suites, including 50L, 250L and 1000L single-use bioreactors dedicated to mammalian cell culture, and a dedicated microbial GMP suite equipped with a 150L stainless steel fermenter and a 300L single-use fermenter expansion capability. The planned addition of the two 2000L single-use bioreactors in Q1 2026 will significantly enhance Bora Biologics' ability to provide seamless scale-up and commercial manufacturing solutions to its clients. 'With this expansion, we will be able to offer our customers 2000L commercial capacity with the ability to purify modern high-titer cell culture processes,' said John R. Mosack, General Manager & Vice President, Operations of the San Diego Site at Bora Biologics. 'In addition to the two 2000L Cytiva bioreactors we are installing now, we will have the space to grow with our customers and meet their evolving needs.' Miguel Carrion, Vice President, Process Development and MS&T at Bora Biologics, added, 'With the addition of the new Cytiva trains, we now have the ability to offer customers both Fisher Single Use and Cytiva Single Use bioreactor trains, providing greater flexibility and options for their specific manufacturing requirements.' cGMPnow, a leading provider of GMP facility design and GxP systems implementation and compliance for the biopharmaceutical industry, is providing process equipment, clean utilities, and automation/controls engineering and commissioning, qualification, and validation expertise for this expansion project. Jeff Gilmore, CEO of cGMPnow, expressed his enthusiasm for the partnership, 'We are absolutely thrilled to be partnering with Bora Biologics on this critical expansion, leveraging our expertise in biopharmaceutical engineering and cGMP compliance to deliver a state-of-the-art facility that will enable their clients to reach more patients.' Cytiva is supplying the advanced bioreactor technology for the expanded facility. Emphasizing Cytiva's support for Bora Biologics' growth, Jordan Heard, Americas Upstream and Consumable Leader (USA) at Cytiva, stated, 'Cytiva is proud to support Bora Biologics in their commitment to innovation and growth. Our XDR bioreactors will provide Bora Biologics with the scalability and flexibility needed to meet the evolving demands of the biologics market.' DPR Construction, a unique technical builder, is applying its skills and experience to the construction of the expanded facility. Scott Sass, DPR's San Diego Business Unit Leader, shared his excitement about the project. 'DPR is excited to partner with Bora Biologics on this project, bringing our expertise in advanced biomanufacturing facility construction to help them expand their capabilities and serve their clients.' This expansion underscores Bora Biologics' dedication to providing its clients with cutting-edge manufacturing capabilities and its commitment to supporting the development and commercialization of life-saving therapies. About Bora Biologics Bora Biologics is a global CDMO offering agile, comprehensive end-to-end solutions for biopharma companies worldwide. With a proven track record of over 100 successful cGMP manufacturing batches, Bora Biologics leverages its state-of-the-art, FDA-registered facility in the U.S. and deep expertise in biologics development and manufacturing - including its own FDA-licensed and Health Canada-approved product - to enhance time and cost efficiencies while ensuring effective pathways to market for its clients. Bora Biologics combines innovative early-phase development and late-stage manufacturing capabilities with the expertise and reputation of Bora Pharmaceuticals for flexible and scalable fill/finish services, including stability testing, and final packaging of clinical and commercial products. About cGMP Now cGMPnow provides turnkey GMP systems, accelerating the delivery of next-generation therapies. Specializing in GMP manufacturing facility design, GxP manufacturing and QC laboratory equipment, GxP computerized systems, commissioning/qualification/validation, and procurement services, cGMPnow utilizes a unique project delivery methodology and owner-focused involvement to bring new products to market faster. With expertise in GMP facility design, construction support, and GxP systems, cGMPnow enables clients to begin production efficiently and effectively, accelerating the delivery of life-changing products. About Cytiva Cytiva is a global biotechnology leader committed to supporting customers in the discovery and commercialization of next-generation therapeutics. As part of Danaher, a global science and technology innovator, Cytiva provides dedicated technical expertise and a comprehensive portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients. About DPR Construction DPR Construction is a forward-thinking, self-performing general contractor and construction manager specializing in technically complex and sustainable projects for the advanced technology, life sciences, healthcare, higher education and commercial markets. DPR's portfolio of work ranges from large-scale new construction to small tenant improvements and special projects. Founded in 1990, DPR is a great story of entrepreneurial success as a private, employee-owned company that has grown to a multi-billion-dollar organization with offices around the world. Strategically focused on delivering more predictable outcomes through applications of virtual design & construction, prefabrication, its team of self-perform craft, and leveraging data to learn and improve from DPR consistently ranks among the top building contractors and employs approximately 11,000 professionals across its family of companies. Contact Information Media Contact [email protected] CDMO Inquiries [email protected] SOURCE: Bora Biologics press release
